Price$30.61-5.74 (-15.79%)
2026-03-042026-06-05
News · 26 weeks510%
2025-12-142026-06-07
Mix3490d
- SEC Filings25(74%)
- Other8(24%)
- Analyst1(3%)
Latest news
25 items- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- ANALYSTSmith & Nephew downgraded by KeplerKepler downgraded Smith & Nephew from Buy to Hold
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- PRSmith+Nephew launch next generation LEAF™ Patient Monitoring System – an innovative pressure injury prevention platform delivering proven clinical impactSmith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces the US launch of next generation LEAF♢ Patient Monitoring System, a data-driven pressure injury prevention platform designed to help health care providers tackle the growing burden of hospital-acquired pressure injuries (HAPIs) by strengthening protocols and outcomes. The LEAF System uses a wearable sensor to monitor patient mobility and provide real-time turn status updates, helping to improve workflow efficiency, turn quality, and protocol adherence.1-3 Every year, approximately 60,000 annual deaths in the US are attributed to HAPIs,4 placing a $26.8B annual burden on the nationwide economy.5 For individu
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- PRA Reno Biotech Just Rang the Nasdaq Bell — Here's Why the Whole Regenerative-Medicine Tape Is Worth WatchingFive companies. One overlapping story. The race to rebuild human tissue is moving from the lab into the public markets — fast. NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — There are weeks when the most interesting story on Wall Street isn't a single ticker. It's the through-line connecting several of them. The week of May 21, 2026 was one of those weeks. A brand-new Nasdaq listing in regenerative tissue arrived in the middle of a cluster of earnings beats, pipeline launches, and product approvals across a handful of related names — all of them, in one way or another, telling the same story: medicine is shifting from "replace" to "regenerate," and
- SECSEC Form SD filed by Smith & Nephew SNATS Inc.SD - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- PRSmith+Nephew drives progress in chronic wound care with ALLEVYN™COMPLETE CARE Dressing and RENASYS™ EDGE tNPWT set to launch at EWMA 2026Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, continues to drive progress in chronic wound management with an industry-leading portfolio set to showcase at the upcoming European Wound Management Association (EWMA) Conference, Bremen between 6-8 May 2026. Demonstrating a long-term commitment to chronic wound management, Smith+Nephew is launching two new wound care innovations designed to support patient outcomes, simplify wound management and ease the clinical burden. This reflects the scale and urgency of a challenge that affects up to 14.9m people in Europe and consumes up to 4% of healthcare spend1. Fully supporting clinicians and patients across the continuum o
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- PRNew data for Smith+Nephew's CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant demonstrates superior pain relief and functional gains at 5-yearsSmith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces further compelling evidence from a multicenter, randomized controlled trial highlighting the clinical superiority of its CARTIHEAL AGILI-C Cartilage Repair Implant recently published in the American Journal of Sports Medicine (AJSM). The CARTIHEAL AGILI-C Cartilage Repair Implant resulted in higher overall Knee injury and Osteoarthritis Outcome Scores (KOOS) versus surgical standard of care* for all time points out to 60 months.1,2 Superior pain relief: Patients treated with the CARTIHEAL AGILI-C Implant reported significantly better knee pain relief, and quality of life improvements over a 5-year perio
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECAmendment: SEC Form 6-K/A filed by Smith & Nephew SNATS Inc.6-K/A - SMITH & NEPHEW PLC (0000845982) (Filer)
SNN FAQ
6 questionsWhat does Smith & Nephew SNATS Inc. do?
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as...Where does SNN stock trade?
Smith & Nephew SNATS Inc. (SNN) is listed on NYSE.What sector and industry is SNN in?
Smith & Nephew SNATS Inc. operates in the Health Care sector, Industrial Specialties industry.What are analysts saying about SNN?
Smith & Nephew SNATS Inc. has had 8 recent analyst actions on file. The most recent action was from Kepler: Hold on 2026-06-04. Recent price targets cluster around $3750.00.What companies are similar to SNN?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare SNN side-by-side with any of them on Quantisnow.How can I track SNN on Quantisnow?
Quantisnow aggregates Smith & Nephew SNATS Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SNN to receive live email and push alerts on every new disclosure.